Host Cell including HEK293, HeLa, CHO, U2OS etc.Plasmid/lentivirus Transduction. Study gene function & design disease models for biopharmaceutical research, etc.
- Black Friday: Up to 25% off For Product/Service
- Reporter Stable Cell Line
GFP, RFP, Luciferase cell lines
In vivo and in vitro imaging study
- Custom Viral Service
Virus vector design & construction
Produce high titer virus particles
- Point Mutation Cell Line
Endogenous knock-in cell lines
used for functional assays, ...
- Genome Editing Services
Including easy-to-handle cells,
tumor cells, stem cells and ...
- Custom Knockin Cell Line
Point mutation cell line
generation service for various ...
- PIK3CD Cell Line
Host Cell including HEK293, HeLa,
CHO, U2OS etc.
Multi-species Pik3ca Protein, Multi-sources &tags, High Purity!
Search results
Mar 1, 2024 · PIK3CA mutations are found in up to 40% of estrogen receptor (ER)-positive, HER2-negative breast cancers. If your tumor is found to have a PIK3CA mutation, new treatments that specifically...
- Jacquelyn Cafasso
Feb 2, 2024 · In a 2019 phase 3 clinical trial (SOLAR-1) published in the New England Journal of Medicine, the combination of Piqray and Faslodex (fulvestrant) almost doubled the progression-free survival rate of people with metastatic breast cancer positive for PIK3CA mutations from 5.7 months to 11.0 months.
Aug 15, 2013 · PIK3CA-related overgrowth spectrum (PROS) encompasses a range of clinical findings in which the core features are congenital or early-childhood onset of segmental/focal overgrowth with or without cellular dysplasia.
- Ghayda Mirzaa, Robert Conway, John M Graham, William B Dobyns
- 2023/04/06
- 2013
Jul 11, 2023 · Citation, DOI, disclosures and article data. PIK3CA-related overgrowth spectrum (PROS) is a broad group of segmental overgrowth disorders that can occur with or without associated vascular anomalies, caused by activating mutations in the PIK3CA gene, which are also responsible for the vast majority of isolated lymphatic malformations and some ...
Mar 31, 2022 · Somatic activating mutations in the gene encoding PI3K alpha catalytic subunit (PIK3CA) are present in approximately 30% of early-stage HER2+ tumors and drive therapeutic resistance to multiple HER2-targeted agents.
The PIK3CA gene provides instructions for making the p110 alpha (p110α) protein, which is one piece (subunit) of an enzyme called phosphatidylinositol 3-kinase (PI3K). Learn about this gene and related health conditions.
People also ask
What is a PIK3CA mutation?
What is PI3K alpha catalytic subunit (PIK3CA)?
What is PIK3CA -related overgrowth spectrum?
How does a PIK3CA test work?
What is PIK3CA treatment?
Does a PIK3CA mutation affect ER+ breast cancer?
PIK3CA. PIK3CA Mutation is present in 12.16% of AACR GENIE cases, with breast invasive ductal carcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, lung adenocarcinoma, and breast invasive lobular carcinoma having the greatest prevalence [4].
